Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01116206




Registration number
NCT01116206
Ethics application status
Date submitted
3/05/2010
Date registered
4/05/2010
Date last updated
21/03/2017

Titles & IDs
Public title
An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation
Scientific title
A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prucalopride (Resolor) Tablets in Participants With Chronic Constipation
Secondary ID [1] 0 0
PRUCRC3001
Secondary ID [2] 0 0
CR017173
Universal Trial Number (UTN)
Trial acronym
Resolor
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Constipation 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Prucalopride
Treatment: Drugs - Placebo

Experimental: Prucalopride - prucalopride 2- milligram (mg), orally once daily for 12 weeks

Placebo comparator: Placebo - Matching placebo, orally once daily for 12 weeks


Treatment: Drugs: Prucalopride
2 mg tablet, orally once daily, for 12 weeks

Treatment: Drugs: Placebo
1 tablet, orally once dailyfor 12 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an Average of 3 or More Spontaneous Complete Bowel Movements (SCBMs)
Timepoint [1] 0 0
Week 1 to 12
Secondary outcome [1] 0 0
Percentage of Participants With an Average of 3 or More SCBMs During the First 4 Weeks
Timepoint [1] 0 0
Week 1 to 4
Secondary outcome [2] 0 0
Percentage of Participants With an Average Increase of 1 or More Bowel Movements (BMs)
Timepoint [2] 0 0
Week 1 to 12
Secondary outcome [3] 0 0
Percentage of Participants With an Average of 3 or More SCBMs During Weeks 5 to 8 and 9 to 12
Timepoint [3] 0 0
Week 5 to Week 8 and Week 9 to Week 12
Secondary outcome [4] 0 0
Average Number of SCBMs
Timepoint [4] 0 0
Week 1 to 12
Secondary outcome [5] 0 0
Average Number of Spontaneous Bowel Movements (SBMs)
Timepoint [5] 0 0
Week 1 to 12
Secondary outcome [6] 0 0
Average Number of all Bowel Movements (BMs)
Timepoint [6] 0 0
Week 1 to 12
Secondary outcome [7] 0 0
Time-to-First SCBM and Time-to-First Week With 3 or More SCBMs After the First Dose of the Study Drug
Timepoint [7] 0 0
Week 1 to 12
Secondary outcome [8] 0 0
Average Number of Bisacodyl Tablets
Timepoint [8] 0 0
Week 1 to 12
Secondary outcome [9] 0 0
Percentage of Participants With Zero, Less Than (<) 2 and Greater Than and Equal to (>=) 2 Tablets of Bisacodyl Taken
Timepoint [9] 0 0
Week 1 to 12
Secondary outcome [10] 0 0
Percentage of BMs With Normal Consistency
Timepoint [10] 0 0
Week 1 to 12
Secondary outcome [11] 0 0
Percentage of BMs With Less Straining
Timepoint [11] 0 0
Week 1 to 12
Secondary outcome [12] 0 0
Percentage of BMs with a Sensation of Complete Evacuation
Timepoint [12] 0 0
Week 1 to 12
Secondary outcome [13] 0 0
Participants Global Assessment on Consistency of Stool
Timepoint [13] 0 0
Week 2, 4, 8 and 12
Secondary outcome [14] 0 0
Participants Global Assessment on Severity of Constipation
Timepoint [14] 0 0
Week 2, Week 4, Week 8 and Week 12
Secondary outcome [15] 0 0
Participants Global Assessment on Efficacy of Treatment
Timepoint [15] 0 0
Week 2, Week 4, Week 8, and Week 12
Secondary outcome [16] 0 0
Investigator's Global Assessment on Efficacy of Treatment
Timepoint [16] 0 0
Week 4 and 12
Secondary outcome [17] 0 0
Change From Baseline in Patient Assessment of Constipation-Symptom Questionnaire (PAC-SYM) Total Score at Week 2, 4, 8 and 12
Timepoint [17] 0 0
Baseline, Week 2, 4, 8, and 12
Secondary outcome [18] 0 0
Change From Baseline in the PAC-SYM Subscale Scores at Week 2, 4, 8 and 12
Timepoint [18] 0 0
Baseline, Week 2, 4, 8, and 12
Secondary outcome [19] 0 0
Percentage of Participant's who Rated Study Drug effectiveness
Timepoint [19] 0 0
Week 2, Week 4, Week 8 and Week 12
Secondary outcome [20] 0 0
Percentage of Participants With PAC SYM Score
Timepoint [20] 0 0
Weeks 2, 4, 8, and 12

Eligibility
Key inclusion criteria
* History of chronic constipation, defined as on average, 2 or fewer spontaneous bowel movements (SBMs) per week and 1 or more of the following for at least a quarter of the time for the last 3 months, while symptom onset was more than 6 months before the screening visit: in more than 25 percent (%) of BMs, participants had very hard (little balls) and/or hard stools, sensation of incomplete evacuation, straining at defecation (making a bowel movement), sensation of ano-rectal obstruction or blockade, and/or need for digital manipulation to facilitate evacuation
* Participants who were considered as constipated (who never had SBMs)
* Participant's constipation is functional
* Participants with the diagnosis of irritable bowel syndrome (bowel disorder in which there is pain and diarrhea or constipation) with constipation and with no other organic diseases can potentially be included depending on the decision of the investigator
* Female participants must be postmenopausal (for at least 1 year) or surgically sterile or practicing a highly effective method of birth control
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Secondary to other diseases/conditions (endocrine disorders, metabolic disorders or neurologic disorders or drug-induced or suspected organic disorders of the large bowel, i.e., obstruction, carcinoma (type of cancer), or inflammatory bowel disease)
* - Participants Using or intending to use disallowed medications that may influence the bowel habit during the study
* Participants with severe (very serious, life threatening) and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer (abnormal tissue that grows and spreads in the body until it kills) or acquired immune deficiency syndrome (AIDS: illness that results in decreased ability of the body to protect itself from other illnesses; development of the disease or conditions associated with the disease results from Human Immunodeficiency Virus [HIV]), or other gastrointestinal or endocrine disorders
* Participants with impaired renal function, that is, serum creatinine greater than 2 milligram per deciliter (greater than 180 micro mole per liter)
* Participants with clinically significant abnormalities of hematology, urinalysis, or blood chemistry

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2011
Sample size
Target
Accrual to date
Final
507
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Box Hill
Recruitment hospital [3] 0 0
- Kingswood
Recruitment hospital [4] 0 0
- Kogarah
Recruitment hospital [5] 0 0
- Newcastle
Recruitment hospital [6] 0 0
- Parkville
Recruitment hospital [7] 0 0
- Prahran
Recruitment hospital [8] 0 0
- Sydney
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Box Hill
Recruitment postcode(s) [3] 0 0
- Kingswood
Recruitment postcode(s) [4] 0 0
- Kogarah
Recruitment postcode(s) [5] 0 0
- Newcastle
Recruitment postcode(s) [6] 0 0
- Parkville
Recruitment postcode(s) [7] 0 0
- Prahran
Recruitment postcode(s) [8] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
China
State/province [1] 0 0
Beijing
Country [2] 0 0
China
State/province [2] 0 0
Chongqing
Country [3] 0 0
China
State/province [3] 0 0
Guangzhou
Country [4] 0 0
China
State/province [4] 0 0
Hangzhou
Country [5] 0 0
China
State/province [5] 0 0
Hefei
Country [6] 0 0
China
State/province [6] 0 0
Jinan
Country [7] 0 0
China
State/province [7] 0 0
Nanjing
Country [8] 0 0
China
State/province [8] 0 0
Shanghai
Country [9] 0 0
China
State/province [9] 0 0
Wuhan
Country [10] 0 0
China
State/province [10] 0 0
Xian
Country [11] 0 0
Korea, Republic of
State/province [11] 0 0
Busan
Country [12] 0 0
Korea, Republic of
State/province [12] 0 0
Dae-Gu
Country [13] 0 0
Korea, Republic of
State/province [13] 0 0
Deajun
Country [14] 0 0
Korea, Republic of
State/province [14] 0 0
Gwangju-Si
Country [15] 0 0
Korea, Republic of
State/province [15] 0 0
Iksan
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Seoul
Country [17] 0 0
Taiwan
State/province [17] 0 0
Taipei
Country [18] 0 0
Thailand
State/province [18] 0 0
Bamgkok
Country [19] 0 0
Thailand
State/province [19] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C Clinical Trial
Address 0 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01116206